A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma

- For patients in Cohort 1: no prior systemic treatment for PDAC

- For patients in Cohort 2: disease progression during administration of either 5-FU− or
gemcitabine-based first-line chemotherapy

- Life expectancy greater than or equal to 3 months

- Availability of a representative tumor specimen that is suitable for determination of
programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central
testing

- Measurable disease (at least one target lesion) according to RECIST v1.1

- Adequate hematologic and end-organ function test results

- Tumor accessible for biopsy

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive measures, and agreement to refrain from
donating eggs, as outlined for each specific treatment arm

- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures, and agreement to refrain from donating sperm, as outlined for
each specific treatment arm

Exclusion Criteria:

- Symptomatic, untreated, or actively progressing central nervous system (CNS)
metastases

- History of leptomeningeal disease

- Active or history of autoimmune disease or immune deficiency

- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening
chest computed tomography (CT) scan

- Positive human immunodeficiency (HIV) test at screening or at any time prior to
screening

- Active hepatitis B or C virus infection or active tuberculosis

- Severe infection within 4 weeks prior to initiation of study treatment

- Prior allogeneic stem cell or solid organ transplantation

- History of malignancy other than pancreatic carcinoma within 2 years prior to
screening, with the exception of those with a negligible risk of metastasis or death